Logo

Theratechnologies Receives Complete Response Letter on the sBLA of Tesamorelin for Abdominal Fat Reduction in HIV and Lipodystrophy Patients

Share this
Theratechnologies

Theratechnologies Receives Complete Response Letter on the sBLA of Tesamorelin for Abdominal Fat Reduction in HIV and Lipodystrophy Patients

Shots:

  • Theratechnologies has received a Complete Response Letter (CRL) from the US FDA on its sBLA of tesamorelin’s F8 formulation for excess abdominal fat reduction in HIV and lipodystrophy patients
  • The CRL raised concerns regarding chemistry and manufacturing & controls (CMC) incl. microbiology, assays, impurities & stability for both the lyophilized and the final reconstituted drug. The US FDA has also requested data demonstrating the impact of the proposed formulation on immunogenicity risk
  • The issued CRL does not affect the commercial availability of EGRIFTA SV (F4 formulation of tesamorelin) for excess abdominal fat reduction in adults with HIV and lipodystrophy

Ref: Theratechnologies | Image: Theratechnologies

Related News:- Palisade Bio Reports P-II Study (PROFILE) Results of LB1148 for Post-Surgical Abdominal Adhesions

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions